Published in Parasitol Res on November 06, 2010
Recent advances in recombinant protein-based malaria vaccines. Vaccine (2015) 0.91
Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors. Clin Vaccine Immunol (2015) 0.81
Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy. Expert Rev Vaccines (2015) 0.76
Current efforts and future prospects in the development of live mycobacteria as vaccines. Expert Rev Vaccines (2015) 0.76
Immunomodulatory effects of recombinant BCG expressing MSP-1C of Plasmodium falciparum on LPS- or LPS+IFN-γ-stimulated J774A.1 cells. Hum Vaccin Immunother (2014) 0.75
New use of BCG for recombinant vaccines. Nature (1991) 14.40
A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med (1990) 4.90
Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis (1996) 3.49
The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem (1996) 3.15
Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med (1997) 2.92
Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med (2001) 2.80
Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol (1999) 2.39
The role of TH1 and TH2 cells in a rodent malaria infection. Science (1993) 2.38
A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg (1998) 2.33
Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun (2004) 2.31
Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis (1998) 2.17
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun (2006) 2.02
Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia (1999) 2.01
A review of human vaccine research and development: malaria. Vaccine (2006) 1.95
Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol (2001) 1.87
Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. Mol Biochem Parasitol (1994) 1.86
Fate of Mycobacterium tuberculosis within murine dendritic cells. Infect Immun (2001) 1.79
High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect Immun (2000) 1.73
Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J Mol Biol (1999) 1.61
A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J Exp Med (2003) 1.61
The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun (2002) 1.56
A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Infect Immun (1996) 1.52
Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J Immunol (1996) 1.49
The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. Mol Cell (1999) 1.40
Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationships with clinical malaria and with entomological inoculation rates. Parasite Immunol (1999) 1.34
Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum. Infect Immun (2006) 1.32
Reciprocal regulation of Th1- and Th2-cytokine-producing T cells during clearance of parasitemia in Plasmodium falciparum malaria. Infect Immun (1998) 1.31
Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg (2006) 1.30
Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses. Infect Immun (2002) 1.19
The immunology of malaria infection. Curr Opin Immunol (2000) 1.19
Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect Immun (2002) 1.13
Regulation of immunity to malaria: valuable lessons learned from murine models. Parasitol Today (1995) 1.09
Antibodies and Plasmodium falciparum merozoites. Trends Parasitol (2001) 1.08
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun (2002) 1.02
Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants. Vaccine (2005) 1.02
A case for whole-parasite malaria vaccines. Int J Parasitol (2007) 0.99
Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli. Infect Immun (2004) 0.98
Field studies of cytotoxic T lymphocytes in malaria infections: implications for malaria vaccine development. Parasitol Today (2000) 0.98
Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus). Microbes Infect (2006) 0.97
A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection. Immunol Rev (1999) 0.97
Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant. Infect Immun (1996) 0.96
Cytokines and malaria parasitemia. Clin Immunol (2001) 0.93
Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine (2005) 0.92
Immunity to erythrocytic stages of malarial parasites. Am J Trop Med Hyg (1994) 0.89
Antibody specificities of children living in a malaria endemic area to inhibitory and blocking epitopes on MSP-1 19 of Plasmodium falciparum. Acta Trop (2008) 0.83
Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1. Vaccine (1999) 0.83
Immune response induced by recombinant BCG expressing merozoite surface antigen 2 from Plasmodium falciparum. Vaccine (2001) 0.80
Immunogenicity of a recombinant Mycobacterium bovis bacille Calmette-Guèrin expressing malarial and tuberculosis epitopes. Vaccine (2006) 0.80
Immunity to blood stages of Plasmodium falciparum is dependent on a specific pattern of immunoglobulin subclass responses to multiple blood stage antigens. Med Hypotheses (2007) 0.79
Humoral response and genetic stability of recombinant BCG expressing hepatitis B surface antigens. J Virol Methods (2005) 0.78
Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines. Food Chem Toxicol (2010) 1.21
Prophylactic effect of administration of human gamma globulins in a mouse model of tuberculosis. Tuberculosis (Edinb) (2009) 1.10
Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine (2011) 1.07
Anticancer activity of a sub-fraction of dichloromethane extract of Strobilanthes crispus on human breast and prostate cancer cells in vitro. BMC Complement Altern Med (2010) 0.98
Antibody mediated immunity - a missed opportunity in the fight against tuberculosis? Malays J Med Sci (2010) 0.90
The importance of animal models in tuberculosis vaccine development. Malays J Med Sci (2011) 0.87
Passive administration of purified secretory IgA from human colostrum induces protection against Mycobacterium tuberculosis in a murine model of progressive pulmonary infection. BMC Immunol (2013) 0.86
Tualang honey promotes apoptotic cell death induced by tamoxifen in breast cancer cell lines. Evid Based Complement Alternat Med (2013) 0.82
Synergistic anticancer effects of a bioactive subfraction of Strobilanthes crispus and tamoxifen on MCF-7 and MDA-MB-231 human breast cancer cell lines. BMC Complement Altern Med (2014) 0.80
Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG. BMC Immunol (2013) 0.80
Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone. Exp Toxicol Pathol (2008) 0.77
Sequence polymorphisms of mtDNA HV1, HV2, and HV3 regions in the Malay population of Peninsular Malaysia. Int J Legal Med (2010) 0.77
In silico identification of common epitopes from pathogenic mycobacteria. BMC Immunol (2013) 0.76
Cell Cycle Modulation of MCF-7 and MDA-MB-231 by a Sub- Fraction of Strobilanthes crispus and its Combination with Tamoxifen. Asian Pac J Cancer Prev (2015) 0.76
Cloning and expression of malaria and tuberculosis epitopes in mycobacterium bovis bacille calmette-guérin. Malays J Med Sci (2006) 0.75
In Silico identification of M. TB proteins with diagnostic potential. BMC Immunol (2013) 0.75
Second international congress on immunopharmacology: delivery systems and current strategies for drug design. BMC Immunol (2013) 0.75
Comparative study of IgA VH 3 gene usage in healthy TST(-) and TST(+) population exposed to tuberculosis: deep sequencing analysis. Immunology (2015) 0.75
Influence of 17β-estradiol on 15-deoxy-δ12,14 prostaglandin J2 -induced apoptosis in MCF-7 and MDA-MB-231 cells. Asian Pac J Cancer Prev (2013) 0.75
Male and female NOD mice differentially express peroxisome proliferator-activated receptors and pathogenic cytokines. Exp Toxicol Pathol (2010) 0.75
Fluoxetine potentiates chloroquine and mefloquine effect on multidrug-resistant Plasmodium falciparum in vitro. Jpn J Infect Dis (2006) 0.75